Search: (WFRF:(Pozzilli C))
> (2020-2022) >
Efficacy of alemtuz...
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
-
Van Wijmeersch, B. (author)
-
Singer, B. A. (author)
-
Boster, A. (author)
-
show more...
-
Broadley, S. (author)
-
Fernandez, O. (author)
-
Freedman, M. S. (author)
-
Izquierdo, G. (author)
-
- Lycke, Jan, 1956 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
-
Pozzilli, C. (author)
-
Sharrack, B. (author)
-
Steingo, B. (author)
-
Wiendl, H. (author)
-
Wray, S. (author)
-
Ziemssen, T. (author)
-
Chung, L. (author)
-
Margolin, D. H. (author)
-
Thangavelu, K. (author)
-
Vermersch, P. (author)
-
show less...
-
(creator_code:org_t)
- 2019-11-01
- 2020
- English.
-
In: Multiple Sclerosis Journal. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 26:13, s. 1719-1728
- Related links:
-
https://research-rep...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods:Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results:Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). Conclusion: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. ClinicalTrials.gov registration numbers:CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Alemtuzumab
- disease-modifying therapy
- relapsing-remitting multiple
- sclerosis (MS)
- efficacy
- magnetic resonance imaging (MRI)
- disability
- interferon
- therapy
- natalizumab
- disability
- disease
- trial
- Neurosciences & Neurology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Van Wijmeersch, ...
-
Singer, B. A.
-
Boster, A.
-
Broadley, S.
-
Fernandez, O.
-
Freedman, M. S.
-
show more...
-
Izquierdo, G.
-
Lycke, Jan, 1956
-
Pozzilli, C.
-
Sharrack, B.
-
Steingo, B.
-
Wiendl, H.
-
Wray, S.
-
Ziemssen, T.
-
Chung, L.
-
Margolin, D. H.
-
Thangavelu, K.
-
Vermersch, P.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Multiple Scleros ...
- By the university
-
University of Gothenburg